▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Keith Speights

TMFFishBiz

Keith Speights is a contributing Motley Fool Healthcare Analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, and marijuana. Prior to The Motley Fool, Speights was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

Recent Articles by Keith Speights

Doctor with tablet and healthcare symbols

Jul 31, 2018 by Keith Speights

Athenahealth, Inc. Earnings Soar Again Thanks to Big Cost-Cutting Moves

The cloud-based healthcare applications provider's second-quarter revenue growth was so-so, but the bottom line improved significantly.

Dart and DNA helix

Jul 30, 2018 by Keith Speights

Illumina Inc. Delivers Another Outstanding Quarter Helped by Strong Consumables Growth

The genomic-sequencing pioneer's momentum continued in the second quarter with strong growth on the top and bottom lines.

Scientists with DNA

Jul 30, 2018 by Keith Speights

Why Arrowhead Pharmaceuticals, Inc. Stock Slumped Today

The clinical-stage biotech stock tanked on no real news, but there are at least a couple of potential culprits.

Listening with hand on ear

Jul 30, 2018 by Keith Speights

Worried About AbbVie? 5 Things the Big Pharma's CEO Just Said You'll Want to Know

AbbVie CEO Rick Gonzalez addresses investors' negativity head-on.

Cutting risk

Jul 29, 2018 by Keith Speights

Why Celgene Is Looking Less Risky and More Attractive

Three reasons the big biotech has become a safer bet for long-term investors.

Marijuana leaves with shadow of dollar sign

Aug 9, 2018 by Keith Speights

7 States That Should Have Billion-Dollar Marijuana Markets by 2022

And a handful of stocks that could profit as these marijuana markets expand.

Marijuana plants on stacks of coins

Jul 29, 2018 by Keith Speights

Better Marijuana Stock: Canopy Growth Corporation vs. Tilray, Inc.

Which stock wins in a one-on-one battle between these two big marijuana growers?

Marijuana growing in greenhouse

Jul 29, 2018 by Keith Speights

Better Marijuana Stock: Aphria vs. Supreme Cannabis

One of these Canadian marijuana growers appears to be in much better shape to capitalize on the big opportunities ahead.

Sleeping man on top of money

Jul 29, 2018 by Keith Speights

3 Cheap Big Pharma Dividend Stocks That You Can Buy Now and Hold for Years

If you have a long-term perspective, these big pharma stocks could be just the ticket.

DNA and world

Jul 28, 2018 by Keith Speights

Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer

How Intellia Therapeutics quickly became one of the top gene-editing biotech stocks on the market.

Charts going up with man looking thru skyscraper window

Jul 28, 2018 by Keith Speights

3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys?

These stocks jumped much higher over the last few days. But should investors jump on the bandwagon?

Frowning face drawing

Jul 27, 2018 by Keith Speights

2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited

AbbVie posts fantastic Q2 numbers but its stock falls. Here's why -- and why the negative reaction is missing the bigger story.

Girl with cystic fibrosis

Jul 27, 2018 by Keith Speights

3 Reasons Why Vertex Pharmaceuticals Stock Isn't Nearly as Expensive as It Looks

The market isn't fully appreciating just how much more room this biotech has to grow.

pointing to news

Jul 27, 2018 by Keith Speights

Forget Gilead Sciences' CEO Departure -- This Was the Biotech's Big News

These four major stories are more important to the biotech's future than its CEO leaving unexpectedly.

Needle pointing to unhappy face

Jul 27, 2018 by Keith Speights

Why Pfizer's Q2 Earnings Results Might Be Weaker Than You'd Like

Don't get your hopes up for a blowout second quarter from the big pharma company.

Pills and money

Jul 26, 2018 by Keith Speights

McKesson Corporation Helped by U.S. Tax Cuts, Hurt by U.K. Reimbursement Cuts

The drug distributor's adjusted profits soared thanks to U.S. corporate tax reform, but it faces even more challenges in Europe.

Doctor with hands over heartbeat

Jul 26, 2018 by Keith Speights

Why Abiomed Inc. Stock Is Sinking Today

The medical-device maker misses Wall Street earnings estimates but continues to rack up impressive revenue growth.

Dentist with patient pointing to smile

Jul 26, 2018 by Keith Speights

Align Technology Inc. Gives Investors Plenty to Smile About With Another Record Quarter

Continued growth for its Invisalign clear aligners and iTero intraoral scanner propel the orthodontic device maker's success.

Woman making decision

Jul 26, 2018 by Keith Speights

Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation

Which stock wins in a one-on-one matchup between these two biotechs?

Face of scientist in lab with beaker

Jul 26, 2018 by Keith Speights

CEO Departure at Gilead Sciences Upstages Good Second-Quarter Results

The big biotech announced great momentum for its new HIV drug, a hint at HCV sales stabilization, and news that its CEO is stepping down.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services